Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to 732.75%.

  • Intellia Therapeutics' EBITDA Margin rose 7079300.0% to 732.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 778.95%, marking a year-over-year increase of 4222500.0%. This contributed to the annual value of 895.5% for FY2024, which is 4166700.0% up from last year.
  • Latest data reveals that Intellia Therapeutics reported EBITDA Margin of 732.75% as of Q3 2025, which was up 7079300.0% from 713.65% recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' EBITDA Margin registered a high of 6825.61% during Q4 2023, and its lowest value of 23935.0% during Q3 2021.
  • In the last 5 years, Intellia Therapeutics' EBITDA Margin had a median value of 821.48% in 2022 and averaged 1741.2%.
  • In the last 5 years, Intellia Therapeutics' EBITDA Margin plummeted by -238091500bps in 2021 and then soared by 230828700bps in 2022.
  • Quarter analysis of 5 years shows Intellia Therapeutics' EBITDA Margin stood at 651.12% in 2021, then dropped by -26bps to 821.48% in 2022, then soared by 931bps to 6825.61% in 2023, then crashed by -115bps to 1022.14% in 2024, then grew by 28bps to 732.75% in 2025.
  • Its EBITDA Margin stands at 732.75% for Q3 2025, versus 713.65% for Q2 2025 and 684.89% for Q1 2025.